HUTCHMED’s shares surged 14.2% in morning trading after the company announced an exclusive global development and licensing agreement with GSK for its experimental cancer drug HMPL-A830.
The deal grants GSK worldwide rights to develop and commercialize the drug outside Mainland China, Hong Kong, Macau, and Taiwan, while HUTCHMED retains full rights within those territories. The total potential deal value is up to $1.295 billion, including an $110 million upfront payment to HUTCHMED’s subsidiary, along with up to $1.185 billion in milestone and royalty payments tied to development, regulatory, and commercial progress.
HMPL-A830 is a first-in-class KRAS-EGFR antibody-targeted therapy conjugate designed to combine monoclonal antibodies with small-molecule inhibitors for dual mechanisms of action against cancer. Acting CEO Johnny Cheng described the agreement as a significant validation of the company’s proprietary ATTC platform, marking its first global licensing transaction.
Initial clinical development will focus on colorectal, pancreatic, and lung cancers, which exhibit high rates of KRAS mutations. A global Phase I program is expected to launch in the second half of 2026. The deal follows recent regulatory progress for HUTCHMED’s other pipeline asset, fanregratinib (ATLED®), which received conditional approval from China’s NMPA for FGFR2-altered intrahepatic cholangiocarcinoma.
The surge in HUTCHMED’s shares dwarfed broader market gains, with the S&P 500 up 0.4%, the Dow Jones rising 0.6%, and the NASDAQ advancing 0.7%. The company also held an investor webcast to provide further details on the agreement and pipeline progress.
